Jane Huang, CMO, Hematology at BeiGene, Ltd. (BGNE), sold 3,080 shares at $358.36 ($1.1M) on 2021-05-28, disclosed to the SEC on 2021-06-02.
Seasonal sale ($1.1M) by CMO, Hematology — this insider has traded BGNE in May in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $352.85 | 100 | $35K | 3.2% |
| 2 | $354.97 | 500 | $177K | 16.1% |
| 3 | $356.21 | 300 | $107K | 9.7% |
| 4 | $357.50 | 353 | $126K | 11.4% |
| 5 | $357.50 | 353 | $126K | 11.4% |
| 6 | $358.36 | 147 |
| $53K |
| 4.8% |
| 7 | $358.36 | 147 | $53K | 4.8% |
| 8 | $359.42 | 100 | $36K | 3.3% |
| 9 | $362.64 | 540 | $196K | 17.7% |
| 10 | $362.64 | 540 | $196K | 17.7% |
| Total | $358.76 avg | 3,080 | $1.1M | 100% |
| Filing → |
| BGNE | SELL | 2021-12-02 | $755K | — | Filing → |
| BGNE | SELL | 2021-11-19 | $572K | — | Filing → |
| BGNE | SELL | 2021-10-21 | $559K | — | Filing → |